http://rdf.ncbi.nlm.nih.gov/pubchem/reference/19442126

Outgoing Links

Predicate Object
contentType Editorial|Comment
endingPage 2126
issn 0732-183X
1527-7755
issueIdentifier 13
pageRange 2125-2126
publicationName Journal of clinical oncology : official journal of the American Society of Clinical Oncology
startingPage 2125
bibliographicCitation Escudier B. How to interpret phase II data for everolimus plus bevacizumab in renal cell carcinoma. J Clin Oncol. 2010 May 01;28(13):2125–6. doi: 10.1200/jco.2009.27.4951. PMID: 20368540.
creator http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ec5aa33f969abf9ff95be6e77ca2062e
date 2010-05-01-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier https://doi.org/10.1200/jco.2009.27.4951
https://pubmed.ncbi.nlm.nih.gov/20368540
isPartOf https://portal.issn.org/resource/ISSN/1527-7755
http://rdf.ncbi.nlm.nih.gov/pubchem/journal/5023
https://portal.issn.org/resource/ISSN/0732-183X
language English
source https://www.crossref.org/
https://pubmed.ncbi.nlm.nih.gov/
title How to Interpret Phase II Data for Everolimus Plus Bevacizumab in Renal Cell Carcinoma
discusses http://id.nlm.nih.gov/mesh/M0457532
http://id.nlm.nih.gov/mesh/M0469193
http://id.nlm.nih.gov/mesh/M000602394
http://id.nlm.nih.gov/mesh/M0029863
http://id.nlm.nih.gov/mesh/M0328153
http://id.nlm.nih.gov/mesh/M0001357
http://id.nlm.nih.gov/mesh/M0443627
http://id.nlm.nih.gov/mesh/M0026339
http://id.nlm.nih.gov/mesh/M0543256
http://id.nlm.nih.gov/mesh/M0556300
http://id.nlm.nih.gov/mesh/M0460178
hasPrimarySubjectTerm http://id.nlm.nih.gov/mesh/D000971Q000627
http://id.nlm.nih.gov/mesh/D017322
http://id.nlm.nih.gov/mesh/D007680Q000188
http://id.nlm.nih.gov/mesh/D002292Q000188
hasSubjectTerm http://id.nlm.nih.gov/mesh/D019317
http://id.nlm.nih.gov/mesh/D000971Q000009
http://id.nlm.nih.gov/mesh/D047908Q000037
http://id.nlm.nih.gov/mesh/D017346Q000037
http://id.nlm.nih.gov/mesh/D002292Q000201
http://id.nlm.nih.gov/mesh/D047908Q000378
http://id.nlm.nih.gov/mesh/D013997
http://id.nlm.nih.gov/mesh/D007680Q000473
http://id.nlm.nih.gov/mesh/D000068338
http://id.nlm.nih.gov/mesh/D000068258
http://id.nlm.nih.gov/mesh/D003627
http://id.nlm.nih.gov/mesh/D007680Q000401
http://id.nlm.nih.gov/mesh/D047428Q000008
http://id.nlm.nih.gov/mesh/D007680Q000201
http://id.nlm.nih.gov/mesh/D012107
http://id.nlm.nih.gov/mesh/D017346Q000378
http://id.nlm.nih.gov/mesh/D000911Q000008
http://id.nlm.nih.gov/mesh/D009367
http://id.nlm.nih.gov/mesh/D016896
http://id.nlm.nih.gov/mesh/D018572
http://id.nlm.nih.gov/mesh/D020123Q000031
http://id.nlm.nih.gov/mesh/D020123Q000008
http://id.nlm.nih.gov/mesh/D020533Q000008
http://id.nlm.nih.gov/mesh/D002292Q000556
http://id.nlm.nih.gov/mesh/D058570
http://id.nlm.nih.gov/mesh/D002292Q000401
http://id.nlm.nih.gov/mesh/D061067
http://id.nlm.nih.gov/mesh/D006801
discussesAsDerivedByTextMining http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7170
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6442177

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID248766214
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128132375
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID242749350

Total number of triples: 68.